Navigation Links
Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/4/2009

CRANBURY, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter and fiscal year 2009 financial results on Tuesday, September 8, 2009, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 8, 2009, which will include discussion of the results of operations in greater detail and an update on corporate developments.

    Schedule for the Financial Results Press Release, Conference Call/Webcast

    - Q4 & Fiscal Year 2009 Financial Results
       Press Release                                 9/8/2009 at 7:30 a.m. ET

    - Q4 & Fiscal Year 2009 Conference Call-Live     9/8/2009 at 11:00 a.m. ET
      Domestic Dial-In Number                        1-800-776-0816
      International Dial-In Number                   1-913-312-0854
      Passcode                                       1405577

    - Q4 & Fiscal Year 2009 Conference Call-Replay   9/8-9/15/2009
      Domestic Dial-In Number                        1-888-203-1112
      International Dial-In Number                   1-719-457-0820
      Passcode                                       1405577

    - Webcast Live and Replay Access                http://www.palatin.com

      The webcast and replay can be accessed by logging on to the
      "Investor/Media Center-Webcasts" section of Palatin's website at
     http://www.palatin.com

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website athttp://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017  If only one in ... a mutation-conferring resistance to chemotherapy, thousands of cancer ... has focused on finding these mutations in ever-smaller ... circulating tumor DNA in blood — to guide ... Unfortunately, however, detecting these genetic anomalies ...
(Date:2/16/2017)... MI (PRWEB) , ... February 16, 2017 , ... Avomeen ... p.m. The event will be held at Avomeen Analytical Services (4840 Venture Dr., ... a MichBio member organization. They provide an opportunity to interact with peers, make new ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/19/2017)... CLARA, Calif. , Jan. 19, 2017 /PRNewswire/ ... company enhancing user experience and security for consumer ... of next-generation payment processing systems and cybersecurity solutions, ... more banks, enterprises and financial institutions worldwide to ... part of the end-to-end secure user authentication platforms ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):